company background image
EQL logo

EQL Pharma OM:EQL Stock Report

Last Price

SEK 55.00

Market Cap

SEK 1.6b

7D

-3.5%

1Y

95.0%

Updated

25 Aug, 2024

Data

Company Financials +

EQL Pharma AB (publ)

OM:EQL Stock Report

Market Cap: SEK 1.6b

EQL Stock Overview

Engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe.

About the company

EQL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 77% below our estimate of its fair value
Earnings are forecast to grow 63.44% per year

Risk Analysis

Debt is not well covered by operating cash flow
High level of non-cash earnings

EQL Pharma AB (publ) Competitors

Humana

OM:HUM

SEK 1.7b

Dedicare

OM:DEDI

SEK 673.2m

C-Rad

OM:CRAD B

SEK 1.5b

SyntheticMR

NGM:SYNT

SEK 1.2b

Price History & Performance

Summary of all time highs, changes and price drops for EQL Pharma
Historical stock prices
Current Share PriceSEK 55.00
52 Week HighSEK 62.00
52 Week LowSEK 24.70
Beta0.72
11 Month Change1.85%
3 Month Change10.44%
1 Year Change95.04%
33 Year Change49.86%
5 Year Change316.67%
Change since IPO848.28%

Recent News & Updates

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Recent updates

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Shareholder Returns

EQLSE HealthcareSE Market
7D-3.5%2.5%1.5%
1Y95.0%37.4%22.2%

Return vs Industry: EQL exceeded the Swedish Healthcare industry which returned 37.4% over the past year.

Return vs Market: EQL exceeded the Swedish Market which returned 22.2% over the past year.

Price Volatility

Is EQL's price volatile compared to industry and market?
EQL volatility
EQL Average Weekly Movement5.8%
Healthcare Industry Average Movement4.1%
Market Average Movement5.7%
10% most volatile stocks in SE Market12.1%
10% least volatile stocks in SE Market3.4%

Stable Share Price: EQL has not had significant price volatility in the past 3 months.

Volatility Over Time: EQL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200622Axel Schorlingwww.eqlpharma.com

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

EQL Pharma AB (publ) Fundamentals Summary

How do EQL Pharma's earnings and revenue compare to its market cap?
EQL fundamental statistics
Market capSEK 1.60b
Earnings (TTM)SEK 26.29m
Revenue (TTM)SEK 290.75m

60.8x

P/E Ratio

5.5x

P/S Ratio

Is EQL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EQL income statement (TTM)
RevenueSEK 290.75m
Cost of RevenueSEK 164.92m
Gross ProfitSEK 125.84m
Other ExpensesSEK 99.54m
EarningsSEK 26.29m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)0.90
Gross Margin43.28%
Net Profit Margin9.04%
Debt/Equity Ratio74.7%

How did EQL perform over the long term?

See historical performance and comparison